Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy

Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.

Detalles Bibliográficos
Autores principales: Meucci, Elisa, Radice, Anna, Fassio, Filippo, Iorno, Maria Loredana Chiara, Macchia, Donatella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529882/
https://www.ncbi.nlm.nih.gov/pubmed/34721849
http://dx.doi.org/10.1002/ccr3.4935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529882/
https://www.ncbi.nlm.nih.gov/pubmed/34721849
http://dx.doi.org/10.1002/ccr3.4935

Ejemplares similares